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Background and aims: Despite the clinical benefits of using standard (non-disease 3 
specific) oral nutritional supplements (ONS) in the community and care homes, there 4 
is uncertainty about their economic consequences.  5 
Methods: A systematic review was undertaken according to recommended procedures 6 
to assess whether ONS can produce cost savings and cost-effective outcomes. 7 
Results: 19 publications with and without a hospital component were identified: 9 full 8 
text papers, 9 abstracts, and 1 report with retrospective analyses of 6 randomised 9 
controlled trials. From these publications a total of 31 cost and 4 cost-effectiveness 10 
analyses were identified. Most were retrospective analyses based on clinical data from 11 
randomised controlled trials (RCTs). In 9 studies/economic models involving ONS 12 
use for <3 months, there were consistent cost savings compared to the control group 13 
(median cost saving 9.2%; P <0.01). When used for ≥3 months, the median cost 14 
saving was 5% (P>0.05; 5 studies). In RCTs, ONS accounted for less than 5% of the 15 
total costs and the investment in the community produced a cost saving in hospital. 16 
Meta-analysis indicated that ONS reduced hospitalisation significantly (16.5%;  P 17 
<0.001; 9 comparisons) and mortality non-significantly (Relative risk 0.86 (95% CI, 18 
0.61, 1.22); 8 comparisons). Many clinically relevant outcomes favouring ONS were 19 
reported: improved quality of life, reduced infections, reduced minor post-operative 20 
complications, reduced falls, and functional limitations. Of the cost-effectiveness 21 
analyses involving quality adjusted life years or functional limitations, most favoured 22 
the ONS group. The care home studies (4 cost analyses; 2 cost-effectiveness analyses) 23 















Conclusions: Overall, the reviewed studies, mostly based on retrospective cost 1 
analyses, indicate that ONS use in the community produce an overall cost advantage 2 
or near neutral balance, often in association with clinically relevant outcomes, 3 
suggesting cost effectiveness. There is a need for prospective studies designed to 4 
examine primary economic outcomes. 5 
 6 
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1. Introduction 1 
 2 
     Malnutrition is a common clinical and public health problem, and at a given point 3 
in time, more than 97% of it exists outside hospital1. It not only produces a burden to 4 
the individuals concerned such as delayed recovery, more complications and 5 
increased dependency on others, but also to the services and the public providing 6 
health and social care support. Whilst the general benefits of treating malnutrition are 7 
well recognised2, 3 and while the effects of specific forms of nutritional support, such 8 
as oral nutritional supplements (ONS)  have been reviewed in the community4, 5 and 9 
in care homes6, information on the economic consequences are limited7-11. An 10 
accurate overview of the cost and cost effectiveness of ONS can be difficult to 11 
establish from the existing reviews7-11 which  have often reported the effects of a 12 
combination of interventions in various care settings, including  tube feeding, 13 
parenteral nutrition, disease and non-disease specific ONS, and others  in which 14 
snacks rather than ONS have dominated. Furthermore, most of the economic analyses 15 
involving standard ONS in hospital and community settings appear to have been 16 
missed, while most of the reviewed studies have been largely based on disease-17 
specific ONS (those specifically modified for particular patient groups), rather than 18 
the standard ONS, which are used in the majority of patients. There are also apparent 19 
contradictions in the cost12 and cost effectiveness 13-15 of  ONS, which may be due to 20 
differences in methodology16, and type of ONS used.  21 
     For patients moving from one care setting to another, the situation can become 22 
complicated because the cost of management in one setting may be offset by a larger 23 
cost saving in another setting. Furthermore, regulatory agencies have identified the 24 















started only when it is appropriate to do so, according to existing evidence or 1 
guidelines, and continued for no longer than is necessary17. To address these issues 2 
there is a need to review the effects of ONS, which may depend on age, disease, 3 
nutritional status and whether or not ONS are given alone or in combination with 4 
other interventions, such as dietary counselling. They may also depend on whether the 5 
investigations are randomised controlled trials (RCTs)14, 18 or observational19 studies 6 
carried out prospectively or retrospectively, and whether ONS are administered 7 
exclusively in the community and care homes, or additionally in other care settings. 8 
The purpose of this systematic review was to critically examine the cost (or cost 9 
saving) and cost effectiveness of standard ONS in the community and care home 10 
settings in the light of the above factors. In particular, it aimed to distinguish between 11 
studies undertaken exclusively outside hospital (e.g. community and care homes), and 12 
those that are started outside hospital and continued in the hospital setting and vice 13 
versa. The review also aimed to identify gaps in the current literature, so that they can 14 
be addressed by future research.  15 
 16 
2. Methods 17 
 18 
2.1. Inclusion and exclusion criteria  19 
     The pre-specified inclusion and exclusion criteria are summarised in Table 1. 20 
Standard ONS was defined as a commercially available, ready to consume, multi-21 
nutrient (complete or incomplete), liquid or semi-solid product providing a mix of 22 
macronutrients and micronutrients produced by specialist medical nutrition 23 
















2.2. Outcomes 1 
     The primary outcome measure of this review was a cost- and/or a cost-2 
effectiveness analysis, irrespective of the type of effectiveness outcomes used (e.g. 3 
Quality Adjusted Life Year (QALY), energy intake or physical activity). The 4 
secondary outcome measures were functional and clinically relevant outcomes. 5 
 6 
2.3. Data extraction  7 
     The literature search was undertaken on 31 March 2014. OvidSP was used to 8 
search Embase (Embase Classic + Embase 1947 to 2014 week 13) and Medline (1946 9 
to 2014 March week 3). The Health Economic Evaluation Database (HEED) and the 10 
Cochrane library (which includes the National Health Service Economic Evaluations 11 
Database NHS EED), Cochrane Database of Systematic Reviews, Cochrane Central 12 
Register of Controlled Trials and Database of Abstracts of Reviews and Effects were 13 
searched on the same date. Articles from all of these databases were exported into a 14 
single ‘library’.  The Cost-Effectiveness Analysis (CEA) Registry was cross checked 15 
independently. The search was undertaken as part of a larger systematic review that 16 
included use of ONS exclusively in the hospital setting20 .  17 
     Three sets of terms were used to search various parts of publications including the 18 
title, abstract, subject heading and any key words. These were: 1. economic, 19 
economics, cost, costs, finance, finances, budget, budgets, expense, expenses, price, 20 
prices, AUD, USD, EUR, GBP, dollar, dollars, euro, euros, pound and pounds, 2. 21 
supplement, supplements, ONS, sip, sips, feed, feeds, nutrition and nutritional; 3. 22 
utility, healthcare, resource, resources, effective, effectiveness, benefit and benefits. 23 
Only articles that included at least one search term within each of the three groups 24 















reading the titles, abstracts and key descriptor words/phrases. They were initially 1 
screened by reading the title and abstract, and if deemed to be potentially relevant the 2 
full article was reviewed. Other publications were identified from prior knowledge, 3 
discussions with experts in the field and hand searching of retrieved full text ONS 4 
papers. The assessment of trial eligibility was undertaken by two independent 5 
assessors and any disagreements were resolved through discussion. The reasons for 6 
exclusion are shown in Figure 1. Authors of several publications15, 21-24 were 7 
contacted to clarify specific issues.  8 
 9 
2.4. Quality assessment 10 
     The procedure for assessing the quality of controlled trials (assessment of risk of 11 
bias) was based on the Cochrane Handbook for Systematic Reviews of Interventions, 12 
updated in 201125. The quality of the economic studies was assessed using the 13 
checklist provided by Drummond et al16, which was adapted for nutritional studies on 14 
the basis that some items were ambiguous or not relevant to the types of studies being 15 
assessed.  Abstracts (see below) were not evaluated for quality because the brief 16 
information provided was considered to be inadequate for the detailed economic 17 
evaluation demanded by the assessment procedure. One full text paper18, which 18 
provided a brief summary of the economic data, indicated that further data would be 19 
forthcoming, but since no such information was identified the study was only 20 
evaluated for the quality of the RCT. Evaluations based on economic criteria were 21 
only undertaken for studies reporting economic outcomes in the original paper and not 22 
those subsequently subjected to secondary analyses to establish economic outcomes. 23 
 24 















     Comprehensive Meta-Analysis (version 2, Biostat Inc. New Jersey, USA) was 1 
used to undertake random effects meta-analyses. When costs were expressed in 2 
different national currency units, such as British pounds and Euros (the value of 3 
which can vary considerably between different European Union countries), two 4 
procedures were undertaken: a forest plot was presented along with the statistics for 5 
each study, but without a summary statistic for the combination of studies; and a 6 
meta-analysis in which the results were expressed as a proportion of the standard 7 
deviation or as a proportion of the control group. When meta-analysis was not 8 
possible due to lack of measures of variation, the mean values from each study were 9 
analysed using standard statistical tests, such as one sample t-tests for the difference 10 
between intervention and control groups and the binomial test; SPSS (version 21, 11 
Chicago, USA). Some results were reported narratively. A P-value of <0.05 (two 12 
tailed) was considered to be significant. Synthesis of data for statistical analyses, 13 
including meta-analyses, did not include abstracts which have obvious limitations. 14 
 15 
3. Results 16 
 17 
     A total of 22,819 potentially relevant publications were identified by the electronic 18 
literature search and another seven by hand searching and expert prior knowledge of 19 
the literature. Figure 1 shows the steps that led to the final 19 publications included in 20 
the review12-14, 18, 19, 21-24, 26-35. Two abstracts of the same study, each with some 21 
complementary information, were considered to represent a single publication23. Of 22 
the 19 publications, nine were full text papers13, 14, 18, 19, 26-29, 35 , nine were abstracts21-23 
24, 30-34
, and one was a report12. Nine publications reported the results of primary 24 















retrospective (post hoc) cost analyses. The British Association for Parenteral and 1 
Enteral Nutrition (BAPEN) report12, which included 10 retrospective cost analyses 2 
from six full text papers of RCTs18, 36-40, was largely based on a published systematic 3 
review of ONS3. Economic data from individual studies in the BAPEN report were 4 
extracted, amalgamated with other data and used to undertake new meta-analyses (the 5 
BAPEN report included no meta-analyses of community studies). The original papers 6 
were also systematically examined for clinically relevant outcome measures (which 7 
were also not reported in the BAPEN report) so that further meta-analyses relevant to 8 
cost effectiveness could be undertaken.  9 
     Overall there were 31 cost analyses (including four analyses in the BAPEN report 10 
based on data from Smedley et al18) and cost-effectiveness analyses (which also 11 
included cost analyses). The number of analyses exceeded the number of publications 12 
for three reasons: some RCTs included more than two arms (e.g. references18, 36 13 
analysed by BAPEN); some results were analysed prospectively by the authors and 14 
retrospectively using different methods by other groups12, 18;  and some cost-15 
effectiveness studies also provided data on overall costs14, 23. Of the 31 cost analyses, 16 
only 17 were identified by the electronic literature search. The remaining 14 were 17 
based on prior knowledge of two full text papers19, 26 (subsequently retrieved using 18 
different search terms), three abstracts21, 22, 24 and the BAPEN report12 with its 10 cost 19 
analyses (not listed). Most of these were not included in previous reviews7-10.  20 
 21 
3.1 General features of the studies 22 
     Supplementary file 1 summarises key features of individual studies.  Both single 23 
and multi-centre studies were undertaken in various European countries and the USA. 24 















malnourished subjects. Most comparisons involved ONS v. no ONS (papers13, 18, 27, 28, 1 
35
 ; abstracts30-32) but a variety of other comparisons were made including: ONS plus 2 
dietary advice plus calcium/vitamin D v. routine care14; ONS plus dietary advice v. 3 
routine care26; ONS v. snacks29; and expenditure in general practices with a history of 4 
high v. low rates of ONS prescriptions19.  Additional comparisons were reported in 5 
some abstracts e.g. ONS v. dietary advice23, or the ‘Malnutrition Universal Screening 6 
Tool’ (‘MUST’) framework of nutritional care which includes ONS v. routine care21, 7 
22
. Some studies began administering ONS in hospital and continued into the 8 
community, others started in the community and continued in hospital, and yet others 9 
were carried out in the community following admission to hospital. Only one clinical 10 
study recruited directly from the community19. 11 
     The cost of screening and assessment, needed to identify subjects for ONS 12 
prescription  and monitoring, appear to have been included in only two abstracts22, 24 13 
(and  personal communication from A Cawood). Economic models examining the 14 
impact of ONS in specific countries typically used national tariffs operating in the 15 
countries and clinical data obtained from various countries with different healthcare 16 
systems (papers27, 28, 35) or from unspecified countries (abstracts24, 30-33).  17 
   Cost  was the primary outcome in one prospectively undertaken clinical study19 and  18 
the secondary outcome in three clinical studies 18, 26, 34, two of which had a hospital 19 
component18, 34. Cost-effectiveness analysis was probably the secondary outcome in a 20 
community study14 (see Supplementary file 1) with some uncertainty as to whether it 21 
was a primary or secondary outcome measure in a care home study29.  Other clinical 22 
studies were designed with non-economic outcomes in mind (Supplementary file 1).  23 
     In studies involving both short-term (<3 months, and as little as 15 days) and long-24 















some patient groups) the reported ONS intake ranged from 259 to 720 kcal/day. Lack 1 
of information prevented calculation of compliance  from both papers/reports14, 18, 19, 2 
29, 38-40
, and abstracts23, 34, but it was possible to estimate that ONS intake accounted 3 
for 50-100% of the target intake in one study (variable intake reported)37 ,34-57% in 4 
another  (variable target intake reported)26, and about 80%13 in a third study. 5 
Adherence to oral nutritional support was reported to be 80% in a further study 14. 6 
Methodological details for assessing intake were usually not provided, but some 7 
studies relied on diaries36 or records kept by patients13. Daily intake was assessed to 8 
the nearest half carton in one study18. Attempts were made to improve compliance in 9 
some studies (e.g.14, 29, 37) but it is unclear if this represented routine practice. In one 10 
study research staff and not regular staff encouraged better compliance29. 11 
 12 
3.2. Outcomes: community (ONS use in community ± hospital)  13 
The results of cost and cost-effectiveness analyses are reported separately below in 14 
sections that consider individual studies first and amalgamated studies next. Care 15 
homes studies are reported in section 3.3. 16 
3.2.1. Cost analysis 17 
 (a)Individual studies 18 
     Short-term, pre-and /or post-operative supplementation studies (<3 months           19 
supplementation): The results of the short-term (<3 months) retrospective analyses of 20 
surgical studies undertaken by the BAPEN group are shown in Table 2. The analyses 21 
uniformly favoured the ONS group when the calculations were based on bed-day 22 
costs or excess bed-day costs (costs of unusually long stays that typically include 23 
basic care and hotel costs but exclude the costs of surgical procedures); and in four 24 















of the original papers briefly reported that in comparison with the control group (no 1 
ONS) there was a net cost saving favouring the group given ONS pre-operatively in 2 
the community (£332/patient) as well as in the group given ONS before, during and 3 
after hospitalisation (£329/patient)18.  These were within the values established by the 4 
BAPEN group using different methodologies based on bed-day and excess bed-day 5 
costs. There was also a cost saving favouring a third group given ONS post-6 
operatively both in hospital and after discharge from hospital , which was more 7 
favourable (£292/patient) than those calculated by the BAPEN group using bed-day 8 
(£260.7/patient) and excess bed-day costs (£130.1/patient). Another primary study 9 
crudely estimated the cost saving associated with a reduction in length of hospital stay 10 
($2,298/patient)38. Finally, an abstract of a RCT in which ONS appears to have been 11 
administered before, during and after hospitalisation reported a significant cost saving 12 
in favour of the ONS (10% cost saving 6 months after surgery which included the cost 13 
of hospitalisation34).  14 
     Long-term, community studies (≥3 months supplementation): Two prospective 15 
economic studies involving use of ONS for ≥3 months were identified. In the multi-16 
centre prospective open label control trial of Edington et al26 there was no significant 17 
difference between the ONS and control group in health and social care costs, or in 18 
the costs of  prescriptions, General Practitioner (GP) consultations, outpatient 19 
appointments and hospital inpatient admissions. In the other RCT, beginning in the 20 
hospital setting and continuing in the community, there was also no significant 21 
difference in costs between the ONS and the control group (€23,353 ±16,124 v. 22 
€22,896±16,834;  direct costs, which accounted for ca. 95% of total costs)14.  23 
     The observational study of Arnaud-Battandier et al19 reported an overall cost 24 















low prescription rates, but the difference was not significant  (€195; 90% CI -€478, 1 
€929 per patient per year). The extra costs of the ONS (€528 per patient per year) 2 
were offset by greater cost savings (€723 per patient per year), predominantly due to 3 
reduced hospital admissions (€551 per patient per year).    4 
     In one of the retrospective analyses undertaken by the BAPEN group, the cost of 5 
ONS  given to  mildly malnourished and hypoalbuminaemic patients who had been on 6 
dialysis for at least 3 months40, was estimated to outweigh the cost saving from 7 
reduced hospitalisation.  In contrast, another analysis involving 51 patients with 8 
decompensated alcoholic liver disease39, the cost of the ONS was considered to be 9 
more than offset by reduced number of days spent in hospital (71, ONS group v. 107 10 
days, control group).  11 
     Economic modelling studies: All publications of economic modelling of ONS 12 
administration used information from previously published clinical studies, and all 13 
favoured the ONS group. The three full text papers are described first27, 28, 35. 14 
     A model for assessing the cost impact of ONS in the Netherlands35, which included 15 
some observational data from the BAPEN economic report12, calculated a net cost 16 
saving of  €252 per malnourished patient undergoing abdominal surgical procedures 17 
(2004 prices inflated to 2008 prices) in favour of the ONS group. The cost of the 18 
supplement, which was assumed to have been taken both in the community pre-19 
operatively and in hospital post-operatively for a total of 17 days, was more than 20 
counterbalanced by the assumed reduction in length of hospital stay. The cost saving 21 
per patient was extrapolated to an annual cost saving in the whole of the Netherlands.  22 
     The second full text paper, which assumed that ONS was administered for 3 23 
months in patients with benign gastrointestinal disease following discharge from 24 















compared to the control group receiving no ONS (€768 based on calculations using 1 
Diagnosis Related Groups (DRG); €791 based on calculations using bed-day costs, 2 
even after taking into account the extra cost of the ONS (€534) (net cost saving, €234 3 
per patient  based on DRG and €257 based on LOS costs (2007 prices)). When 4 
extrapolated to the whole of Germany, the overall annual savings were  €604 million, 5 
using DRG costs,  and €681 million, using bed-day costs. The calculations were 6 
dominated by hospital readmission rates over a 6 month period, which were taken to 7 
be significantly lower in the ONS group (26.3% v. 47.6%). The clinical data were 8 
largely based on a German study41 but a UK study was also used in sensitivity 9 
analyses, which consistently favoured  the ONS group.  10 
     The third full text paper28, using a similar type of model as the previous one27, 11 
assumed that ONS (600 kcal/day) were administered  for 3 months to malnourished 12 
community dwelling subjects ≥65 years, considered to represent 20% of the home 13 
care population in the Netherlands. The model further assumed that the intervention 14 
would reduce hospitalisation by 25% on the basis of three RCTs. Two of these 15 
recruited patients recently discharged from hospital41, 42, one involving patients with a 16 
mean age <65 years41, and the other42 a mixture of malnourished and non-17 
malnourished older subjects, who started taking ONS in hospital and then continued 18 
them in the community. The third study used ONS in the community for 12 months43, 19 
or four times longer than the model specification. The base case analysis favoured the 20 
ONS group (€90.15 per malnourished patient (calculated using the data provided)). 21 
Sensitivity analyses almost always favoured the ONS group.  22 
     All four abstracts24, 30-32 of economic modelling involving ONS administration in 23 
the community also favoured the ONS group. One of these24 based on clinical data 24 















(≥65 years) community dwelling patients at risk of malnutrition in England would 1 
produce   a net annual cost saving of £16 million favouring the ONS group. The three 2 
other abstracts comparing the effects of  ONS (taken over an unstated period) v. no 3 
ONS in community dwelling older people (>65 years) reported the following net cost 4 
savings in favour of the ONS group: 18.9% or €13.3 million in the Netherlands31; 5 
12.8% or €173 per patient in the Netherlands30; and 13.0% or €179 per patient or a 6 
total of €344 million in Germany32. 7 
(b) Amalgamated studies 8 
     Subject level analyses (based on meta-analysis of studies comparing mean ± sd 9 
between groups): Figure 2 shows two forest plots of subject level analyses based on 10 
prospective cost analyses of supplementation studies in the community (± in hospital). 11 
The upper forest plot shows the absolute difference in costs, expressed in national 12 
currency units, between ONS and no ONS (or routine care), while the lower forest 13 
plot shows the results expressed as standardised differences with no significant 14 
differences between groups  (see Supplementary file 1 for further meta-analyses).. 15 
     Study level analysis (based only on the difference in mean values between groups): 16 
The amalgamated study results were based only on full text papers and those 17 
presented in the BAPEN report, which were based on retrospective cost analyses of 18 
full text papers12. In an attempt to provide an overview of the average results of 14 19 
cost analyses based on studies undertaken in different countries at different times 20 
using various currencies, the results were expressed as percentage cost savings. Since 21 
the distribution of these cost savings was highly skewed the results were analysed 22 
non-parametrically. Overall, there was a significant cost saving (median 8.1% (inter-23 
quartile range 9.3; P = 0.022; N = 14 analyses)) in favour of the ONS group. When 24 















studies, 13 out of 16 cost analyses favoured the ONS group (P = 0.021). There was no 1 
significant relationship between cost saving on the one hand and year of publication 2 
of study or the duration or estimated duration of supplementation on the other. The 3 
results of individual studies (Table 3) were used to undertake subgroup analyses 4 
according to patient characteristics (age category and nutritional status) and study 5 
design (type of intervention, care setting), which are presented in Table 4. Overall, the 6 
cost saving favoured the ONS group which was significant for the following 7 
subgroups: short-term studies (often with a hospital component); those involving 8 
younger groups of patients; those retrospectively analysed; and those comparing ONS 9 
with no ONS.  Several subgroup analyses were not significant, especially when one 10 
particular study with a large financial loss26 was included in the subgroup analysis.  11 
     Although abstracts of community studies were not included in the above analyses, 12 
they all favoured the ONS group24, 30-32, 34.   13 
(c) Distribution of costs 14 
     In the RCTs that pre-planned to undertake a cost analysis, ONS administration for 15 
0.5-3.1 months, contributed to only 1% - 11% of the total cost (mean <5%), while 16 
hospitalisation contributed to 69% - >90% of the costs (Table 5). In the only 17 
observational study  in which ONS was estimated to have been administered for 18 
longer than 3 months, and perhaps ≥6 months (see footnote to Table 5), ONS 19 
contributed to 23% of the costs, and  hospitalisation to 63% of the costs. All six cost 20 
analyses summarised in Table 5 involved administration of ONS either exclusively or 21 
predominantly in the community. One cost analysis14, in which ONS was started in 22 
hospital and continued ONS for a much longer period, in the community, reported 23 
















3.2.2. Cost-effectiveness analysis 1 
     In an attempt to relate the cost outcomes reported above  to effectiveness measures, 2 
a variety of clinically relevant outcomes from the same studies are summarised below. 3 
The more formal cost-effectiveness (cost-utility) analyses, typically with cost 4 
effectiveness acceptability curves, 13, 14 are presented subsequently. 5 
(a) Clinically relevant benefits 6 
     Anthropometry: Individual studies involving use of ONS in the community (with 7 
or without additional use in hospital), reported significantly greater improvements in 8 
anthropometry in the ONS than control group: weight 18; weight, skinfold thickness 9 
and mid arm muscle circumference37; and nutritional status assessed by MNA19. 10 
Edington et al26 reported significant improvements in weight, skinfold thickness, and 11 
mid-arm circumference in the ONS group but not in the control group, and Neelemaat 12 
et al14 reported a tendency for greater weight gain in the ONS group, which was 13 
significant only for the highest weight subgroup44. 14 
     Hospitalisation: Two studies reported significant reduction in the number of 15 
hospital admissions13, 39.  Other studies reported hospitalisation in different ways e.g. 16 
number of days in hospital including ICU14; total number of days in hospital during 17 
the observational period from which the proportion (and standard deviation of this 18 
proportion) of the time spent in hospital during the study period could be calculated40.  19 
A series of meta-analyses involving 10 datasets from eight publications13, 14, 18, 19, 26, 39, 20 
40, 45
 found reduced hospitalisation in favour of the ONS group. For the nine datasets 21 
from full text papers only it was reduced by 16.5% ((se 4.0), P = 0.001; N = 1051 22 
subjects; I2 = 16%, P = 0.307) (Figure 3). Further meta-analyses, including those 23 
involving only long-term studies, only short-term studies and only RCTs also 24 















     Mortality:  Mortality was reported in seven studies13, 14, 18, 26, 36, 37, 39 (53 deaths in  1 
ONS group and 59  in the comparison group; no deaths in two other studies18, 37, but a 2 
meta-analysis showed no significant differences between them (Relative risk 0.859 3 
(95% CI, 0.606, 1.217), P = 0.393; I2 = 0%, P = 0.825; 7 datasets, N= 943). The 4 
results remained non-significant when the only observational study was excluded 5 
(Relative risk 0.924 (95% CI, 0.556, 1.534), P = 0.706; I2 =0%, P = 0.743) or when 6 
the only pre-operative supplementation study (ONS given in the community) was 7 
excluded (Relative risk 0.853 (95% CI, 0.598, 1.216), P = 0.380; I2 = 0%, P = 0.587). 8 
     Quality of life: The study of Beattie et al37 which started ONS in hospital (used for 9 
<12 days) and continued for 51 days in the community, reported significant 10 
improvements in physical and mental health, assessed using the quality of life 11 
questionnaire SF-36 (36-item  Medical  Outcomes Study Short Form Survey), 12 
favouring the ONS group (P<0.001). In the community study of Norman et al13 there 13 
was a significant gain in QALYs favouring the ONS group, but since there was only 14 
one death out of 60 in the intervention group and three deaths out of 54 in the control 15 
group, almost all the variability in QALYs was due to quality of life. The main 16 
analysis undertaken by Neelemaat et al14 appears to have excluded patients who died, 17 
implying that QALYs gained were based entirely on quality of life. From the statistics 18 
provided it would appear that there was a strong tendency for the changes to favour 19 
the ONS group (by 0.02 (95% CI, 0.00, 0.04) QALYs).  A peri-operative study18 and 20 
a community study in elderly subjects26 reported no significant differences in quality 21 
of life between groups. 22 
     Other Outcomes: Of the eight RCTs reporting functional or clinical outcomes, all 23 
found at least one outcome significantly favouring the ONS group and none 24 















in comparison with the control group, the ONS group significantly improved in 1 
functional limitations by 0.72 units on a scale of 0 to 6,  and a related  paper of the 2 
same study reported significant reductions in the number of falls46 (0.21 v. 3 
0.55/patient; P <0.01). Edington et al26 reported a greater proportion of patients with 4 
no mobility problems at 6 months (32.4 v. 7.7%; P = 0.022) and Hirsch et al39 a 5 
significant reduction in number of infections, although not in the total number of 6 
complications. Grip strength improved in favour of the ONS group, at least at some 7 
point during the course of certain investigations13, 26 but not others14, 39 (in one of 8 
them14 this was reported in an earlier publication of the same RCT44). In one of the 9 
studies13 the increase in grip strength was accompanied by an improvement in peak 10 
expiratory flow13 (also reported in an earlier publication of the same RCT41). In 11 
surgical studies18, 34, 36, 37 in which ONS was administered pre- and/or post-operatively 12 
in the community, and in some cases during elective hospital admissions, significant 13 
benefits were frequently reported. Smedley et al18 found a  significant reduction in 14 
minor complications (but not major complications) in the absence of significant 15 
differences in quality of life and fatigue scores between the groups studied. Manasek 16 
et al 34 also reported in abstract form clinical benefits favouring the ONS group (× 2.9 17 
reduction in wound dehiscence, ×2.9 in anastomotic dehiscence, ×1.8 wound 18 
infection, and ×1.8 re-hospitalisation) without p-values).  19 
(b) Cost-utility analysis 20 
     Cost-effectiveness analyses involving QALYs were reported in only two 21 
community studies, which recruited patients from hospital and evaluated the costs 22 
only after discharge from hospital. Further details are shown in Table 6. In one of the 23 
studies13, the  mean ‘cost/QALY’ (extra cost per QALY gained) was sufficiently low 24 















effectiveness acceptability curve (CEAC) was such that the authors concluded that the 1 
intervention was cost effective (with an assumed threshold value of €50,000 there was 2 
about 90% probability that the intervention was cost effective, and with a threshold 3 
value  of €20,000, the CEAC showed there was about 80% probability).The analysis 4 
of this economic ‘pilot study’ considered only the costs of the ONS. The much larger 5 
cost savings, due to the significantly reduced re-hospitalisation rates favoured the 6 
ONS group27,  were not included in the calculations. 7 
     In the other study involving older patients44 the mean ‘cost/QALY’ in the main 8 
analysis, which involved multiple imputation for missing data, was €26,962, and for 9 
‘cost/unit’ improvement in functional limitation was €618. On the assumption that in 10 
the Netherlands an investment of less than €20,000 is cost effective, the authors 11 
concluded that the intervention was cost effective in improving functional limitations 12 
but not in QALYs or physical activity.  13 
     Two other studies18, 26  measured costs and quality of life but no cost-utility 14 
analyses were presented. 15 
 16 
3.3. Outcomes: care homes 17 
     Five publications with economic results relevant to ONS administration in care 18 
homes21-23, 29, 33 were identified, only one of which was a full text paper29. Since they 19 
differed widely in their designs and methodology, no attempt was made to produce 20 
summary statistics from meta-analyses of other types of analyses.  21 
(a) Cost analysis 22 
     Of the four prospective care home cost-analyses reported in abstracts, two were 23 
based on RCTs 23, 29 and the other two on studies with a ‘before and after’ design21, 22. 24 















months of intervention with ONS in care homes in England, the intervention being 1 
implementation of the ‘MUST’ framework, which included screening and use of ONS 2 
in those participants identified as malnourished. One of these studies21 reported a 3 
significant reduction in the cost of hospitalisation in favour of the intervention (£599 4 
over 3 months) but the calculations did not include the cost of ONS. The other study 5 
with a ‘before and after design’22 also  included the cost of screening, management 6 
and monitoring of residents, reported  a net cost saving of £187.91/resident over 3 7 
months (£751.64 annually).  Like the above studies, a cost saving in favour of the 8 
ONS group was also reported in the only retrospective cost analysis of care home 9 
residents using an economic model32. In comparison with no ONS, use of ONS for an 10 
unspecified period of time reduced total costs from €16,617 to €15,453 /resident 11 
(€1,164 /resident (7.0%)), but no details of the clinical studies underpinning the model 12 
or its assumptions were provided in the abstract. In contrast,  a prospective cost 13 
analysis involving a RCT of  care home residents identified as being malnourished 14 
using ‘MUST’23,  reported that the overall costs including those of hospitalisation was 15 
greater in the ONS group than the dietary advice group (£376±214 v. £174±240 16 
/patient over the 3 month period using an intention to treat analysis involving multiple 17 
imputation). The cost-effectiveness analysis of this study is reported below. 18 
(b) Cost effectiveness analysis 19 
Two cost-effectiveness analyses in care homes were identified, one from the USA29 20 
and the other in the UK23, both of which were  based on RCTs. The UK study (a cost-21 
utility study), which established QALYs from a combination of mortality and quality 22 
of life using EQ-5D (EuroQol five dimension scale), found that ONS was cost 23 
effective compared to dietary advice. The incremental cost effectiveness ratio (‘extra 24 















threshold of ~£25,000.  In the USA study29, in which 54% of care home residents had 1 
dementia, the incremental (above baseline measurements) between meal costs (extra 2 
costs for fluid, food and labour) were $0.03/patient/day for the control group 3 
receiving routine care, $2.10/patient/day for the ONS group, and $2.06/patient/day for 4 
the ‘snack’ group. The effectiveness outcome measure was total calories gained, 5 
which was reported to be greater in the snack group (paradoxically with the smallest 6 
weight gain; 0.04 kg) than the ONS group (with the largest weight gain; 2.04 kg). 7 
Given the willingness to pay is $0.04 for each extra kcal gained, the probability of 8 
‘benefit’ (compared to the control group) was 80% for the snack group and 65% for 9 
the ONS group. Therefore, both forms of nutritional support had a ‘beneficial’ effect. 10 
The authors concluded that snacks may be more cost-effective at increasing energy 11 
intake than ONS, but they acknowledged that the sample size of their ‘pilot study’ 12 
was small. The composition of the between meal snacks was not reported, so cost 13 
effectiveness associated with the intake of other nutrients could not be assessed.  14 
 15 
3.4. Assessment of risk of bias 16 
     The overall risk of bias of the included controlled trials and observational studies 17 
was judged to be at least moderate. The supplementary file 2 provides an assessment 18 
of individual studies based on economic criteria as well as criteria for randomised 19 
controlled trials and observational studies.  20 
 21 
4. Discussion 22 
 23 
     This review of studies, mainly of randomised controlled clinical trials, suggests 24 
that the use of standard ONS in the community, with or without additional use in 25 















neutral balance. These cost outcomes were associated with clinically relevant benefits 1 
such as improved quality of life, reduced infections, reduced minor post-operative 2 
complications, reduced falls, and functional limitations  Indeed, most cost analyses 3 
based on full text papers (and all abstracts) favoured the ONS group even when 4 
considered in subgroups according to nutritional status and age, study design, duration 5 
of intervention and setting. This comprehensive review also emphasises the 6 
importance of involving specialists in the field, who identified many analyses from 7 
detailed national reports and other papers that were not retrieved from the electronic 8 
literature searches.  9 
 10 
4.1. Community studies  11 
     The direct contribution of ONS to total expenditure in the community studies was 12 
found to be small, but their potential beneficial impact on the budget was large. For 13 
example, hospitalisation, which dominated the expenditure (Table 5), was 14 
significantly reduced by ONS (meta-analysis; Figure 3). Practical difficulties in 15 
prescription and reimbursement may arise if there are separate funding streams, so 16 
that the community absorbs the prescription costs while hospitals profit from a 17 
reduced workload resulting from fewer complications or fewer re-admissions. 18 
Furthermore, since various reimbursement schemes exist within and between care 19 
settings in different countries, which may affect access to ONS, a single budget that 20 
follows the patient  may help overcome such problems47.   21 
     Although this review is primarily concerned with ONS, the interventions 22 
sometimes included other components, such as dietary advice, additional vitamin D 23 
and calcium supplementation. This means that it is not always possible to ascribe all 24 















ONS provided in the community from that provided to the same patients in another 1 
setting e.g. started in the community pre-operatively and continued in hospital post-2 
operatively or vice versa. A further point is the comparison of ONS v. no ONS which 3 
featured  in  most clinical studies (papers13, 18, 27, 28, 35 ; abstracts30-32), and all but one 4 
of the economic modelling studies (abstract24). This may not represent the situation in 5 
real practice because ONS may already be given to some vulnerable and 6 
malnourished patients, although the extent varies by region, country, speciality and 7 
time. Furthermore, the costs associated with screening and assessment to identify the 8 
study population appear to have been largely ignored,  despite their clinical and 9 
economic importance48. More sophisticated models could address the concerns of 10 
regulatory agencies and advisory bodies about possible inappropriate ONS 11 
prescriptions, and also the need to regularly monitor patients so that  ONS are not 12 
administered for longer than is required17. Such bodies also recommend taking 13 
measures to ensure that malnourished subjects do not go unrecognised and untreated.  14 
 15 
4.2 Care homes 16 
     It is difficult to evaluate the cost effectiveness of ONS at improving energy intake, 17 
from the only full text paper (a pilot study) examining the effects of between meal 18 
interventions29. This is partly because of potential methodological problems, including 19 
small sample sizes. Furthermore, the intake of a range of nutrients that were not 20 
evaluated, may be just as important clinically as energy intake. Four abstracts 21 
suggested favourable effects of ONS on costs and one on cost-effectiveness compared 22 
to simple dietary advice and QALYs gained as the effectiveness outcome measure. 23 
Until the full reports of these studies become available and the literature expanded 24 
















 4.3 General issues concerning community and care home studies 2 
All the economic models based on retrospective cost analysis of a range of clinical 3 
data reported favourable cost outcomes in both community and care home settings,  4 
and several of these have been extrapolated to establish national cost savings, for 5 
example in models of people receiving standard ONS in the community28 or 6 
community and hospital 35 in the Netherlands. Whilst such models can serve a very 7 
useful purpose, they also have limitations. None of the reviewed modelling studies 8 
appear to have established templates based on systematic reviews of clinical studies, 9 
raising the possibility of selection bias i.e. use of specific clinical studies with 10 
favourable outcomes. Among the other limitations were extrapolations from certain 11 
study populations to others (e.g. from one age group to another, from a population of 12 
malnourished and non-malnourished subjects to malnourished subjects alone) and for 13 
periods of ONS use that fell well outside the range specified in the models. In 14 
addition, the models used the national tariffs of the country they aimed to target, but 15 
often obtained the clinical data from other countries with different healthcare systems. 16 
    The limited data on actual and target ONS intake prevented a detailed assessment 17 
of compliance (estimated to be 34-100% in 3 studies). A separate systematic review49 18 
reported 37-100% ONS compliance (mean of 81% for community studies) but the 19 
extent to which this reflects study conditions rather than those operating in routine 20 
clinical care is uncertain. The same applies to the present systematic review. 21 
     A substantial part of the evidence base was established using only simple 22 
economic calculations or theoretical models lacking the robustness of prospective full 23 
economic analyses that incorporate costs of screening plus assessment and 24 















that were primarily undertaken to address non-economic issues. Among the reviewed 1 
clinical studies only one observational study was clearly identified  in which the 2 
primary outcome was economic19, and only  a few 18, 26, 34 (probably including  3 
Neelemaat et al14) in which it was a secondary outcome. The potential overall risk of 4 
bias was judged to be at least moderate. The extent to which potential bias (including 5 
publication bias) of industry and non-industry funded projects may differ is difficult 6 
to assess without further information.  7 
 8 
4.4. Future research 9 
The reviewed studies, mainly based on retrospective analyses, generally suggest that 10 
economic and clinical effects favour the ONS group, but the economic evidence base 11 
in the community and care home settings needs strengthening through prospective 12 
studies with primary economic outcome measures and expansion of the range of 13 
population groups studied. The shortage of economic studies in care homes and the 14 
lack of studies in children need to be addressed. In addition, economic models need to 15 
be extended to take into account the benefits that may occur when ONS are compared 16 
to routine practice rather than no ONS, and also the extent to which they depend on 17 
the method of recruitment. For example, all three RCTs with prospective cost or cost-18 
effectiveness analyses in the community (excluding surgical studies in which the 19 
study design was based on hospital admissions) involved recruitment from the 20 
hospital setting13, 14, 26, generally after an acute illness or an acute stress. In one of 21 
these14, ONS administration began in hospital44, raising the possibility of a carry-over 22 
effect into the community. Although recruitment from hospital may be convenient, it 23 
does not represent the general population of malnourished subjects in the community, 24 















reviewed paper with a prospective cost-analysis with direct recruitment from the 1 
community was an observational study19  which reported a non-significant cost 2 
advantage (€195/patient/year) in malnourished subjects registered with practices with 3 
high rather than low ONS prescriptions rates. In the meantime there is a clinical need 4 
to reduce the extent to which malnutrition goes undetected and untreated. The extent 5 
to which this can be achieved cost effectively by education and training, inspection 6 
and regulation, and incentivisation (e.g. by providing a bonus for high quality care 7 
and penalising inadequate care), requires investigations in the light of the type of 8 
healthcare system operating in different countries. 9 
 10 
5. Conclusion      11 
 12 
     This systematic review with meta-analysis suggests that use of standard ONS in 13 
the community, with and without additional use in hospital, can produce favourable 14 
financial outcomes and can be cost effective.  There is a need to embed appropriate 15 
nutritional support with ONS into routine clinical practice, and to undertake more 16 
high quality studies to further define the patient groups likely to benefit from 17 
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Table 1  1 
Summary of inclusion and exclusion criteria 2 
 Inclusion criteria Exclusion criteria 
Population - Any setting in the community e.g. 
care home, free-living individuals, 
sheltered accommodation 
- Aged ≥ 1 year of age 
- Any nutritional status (well-
nourished, malnourished or at risk 
of malnutrition) 
- Animal studies 
- Pregnancy and lactation 
Intervention - Oral nutritional supplements 
(ONS) alone or with other oral 
nutrition interventions such as: 
- Dietary counselling (dietary 
advice) 
- Provision of special menus 
and/or snacks (e.g. 
energy/protein enriched) 
- Supplements containing vitamins 
and/or minerals only (single or 
multi-nutrient) 
- ONS in combination with enteral 
tube feeding 
- Non-commercially available or 
home-prepared ONS  
- Studies including exercise as an 
intervention and sports studies 
- Disease-specific ONSa including  
  ”immunonutrition” b 
- ONS in combination with drug 
therapy such as anabolic hormones 
- Parenteral nutrition 
- Enteral tube feeding alone 
- Supplementation with vitamins 
and/or minerals only (single or 















 Inclusion criteria Exclusion criteria 
Comparison - ONS v. no ONS 
- ONS + other nutrition 
intervention(s) v. other nutrition 
intervention(s) alone 
- ONS v. routine care (which may 
include some ONS) 
- ONS v. other nutrition 
intervention e.g. dietary advice 
- ONS v another ONS 
Publications - Full text paper, abstracts and 
   reports in the English Language 
- Language other than English  
a Disease-specific ONS include those with macro- and micronutrient compositions adapted to the needs of a 1 
specific disease and/or digestive or metabolic disorder (can be either nutritionally complete or incomplete).   2 
b Immune modulating formulae contain substrates to modulate (enhance or attenuate) immune functions 3 
(also known as immunonutrition, immune-enhancing diets or pharmaconutrition, and typically include 4 















Table 2 1 
Summary of net cost saving due to perioperative ONS administration in the community (± hospital) (data from BAPEN report12) 2 
Studies Na Method of calculationb 























Pre-operative (community)           
Smedley et al 200418 85 440.6 350.8 521.2  190.9  13.3 1.3 25.2 
MacFie et al 200036 49 330.1 273.4 391.7  140.4     
Flynn et al 198738 40 1113.1 583.7 1401.5  745.8     
Pre-operative (community) 
+ post operative  (hospital )    
          
Smedley et al 200418 76 853.2 687.6 1002.0  392.2  113.4 81.5 145.3 
MacFie et al 200036 49 704.8 591.3 827.9  325.4     
           
Pre-operative (community) 
+ post-operative (hospital & community) 















Studies Na Method of calculationb 























Smedley et al 200418 76 899.2 733.6 1048.1  327.6  -79.5 -85.7 -73.3 
           
Post-operative (hospital & community)           
Beattie et al 200037 101 668.2 476.3 815.5  244.5  64.82 -8.9 96.5 
Smedley et al 200418  76 260.7 213.3 304.8  130.1  157.6 125.7 189.5 
a
 N refers to the total number of subjects in the control and intervention groups.  1 
b
 Both bed-day and excess bed-day costs are based on length of hospital stay. Excess bed-days relate to admissions with prolonged length of stay (above the 2 
Healthcare Resource Group trim point) and they are usually associated with lower costs than bed-day costs, as they generally involve basic care and hotel costs. 3 















Table 3 1 
Retrospective cost-analyses of community studies comparing ONS with control groupa 2 
Studyb N Setting Cost saving 
per subject 

















Comparison ONS use 
(months) 
Smedley et al 200418  85 C(pre-op) £440.6 b 9.2 M + NM <65 y I Multi ONS v no ONS <3 mo 
MacFie et al 200036  49 C(pre-op) £330.1 b 7.3 M + NM ≥65 yd I Single ONS v no ONS <3 mo 
Flynn et al 198738  36 C(pre-op) £1113.1 b 13.7 M <65 y I Single ONS v no ONS <3 mo 
Smedley et al 200418 76 C(pre-op)H £853.2 b 16.2 M + NM <65 y I Multi ONS v no ONS <3 mo 
MacFie et al 200036 49 C(pre-op)H £704.8 b 14.4 M + NM <65 yd I  Single ONS v no ONS <3 mo 
Freijer & Nuijten 201035 Model C(pre-op)H €252.0 b 7.6 M  I O Multi ONS v no ONS <3 mo 
Smedley et al 200418 76 C(pre-op)HC (post-op) £788.5 b 14.9 M + NM <65 y I Multi ONS v no ONS <3 mo 
Beattie et al 200037 101 HC(post-op) £668.2 b 8.5 M <65 y I Single Otherf <3 mo 
Smedley et al 200018 79 HC(post-op) £260.7 b 4.9 M + NM <65 y I Multi ONS v no ONS <3 mo 
Neelemaat et al 201214 184 HC(post-discharge) - €403.0 -4.9 M  ≥65 y I Single Other ≥3 mo 
Edington et al 200426 100 C -£1159.34 b -54.0 M  ≥65 y I Multi Other ≥3 mo 
Arnaud-Battandier et al 199919 378 C €195.0 7.2 M ≥65 y O Multi Other ≥3 mo 















Studyb N Setting Cost saving 
per subject 

















Comparison ONS use 
(months) 
Freijer et al 201228 Model C €90.1 4.7 M ≥65 y I Multi ONS v no ONS ≥3 mo 
Hirsch et al 199339 51 C ˗ (loss) b loss M + NM <65 y I Single ONS v no ONS ≥3 mo 
Wilson et al 200140 32 C + (saving) b saving M <65 y I Multi Other ≥3 mo 
a Only full text papers and analyses of full text papers in reports are included. 1 
b
 Details of the retrospective economic analyses can be found in the BAPEN report12 2 
c
 Positive values indicate that the net balance favours the ONS group (lower cost in the ONS group than the comparison group) and the negative sign, the 3 
comparison group (higher cost in the ONS group than the comparison group) 4 
d
 Based on average of the mean age of the groups involved 5 
e
 largely based on study41 in which the mean age was <65 years 6 
H = Hospital; C = Community; pre-op = pre-operative; post-op = post-operative. The sequence indicates the order in which ONS was administered (e.g. HC = 7 
hospital first and then community); M = malnourished; NM = non-malnourished; I = interventional; O = observational 8 
f















Table 4 1 
Cost saving (study level analysis) in favour of the ONS group by age, nutritional status 2 
and study designa 3 
  % cost-saving (continuous data) Cost saving (binary data)  











< 65 years  8 13.9 (11.2)d 0.012  9/10 0.021 
>65 years  5 4.7 (36.7) 0.893  3/5 1.000 
        
Malnourished  8 7.4 (14.1) 0.893  8/9 0. 039 
Malnourished + non malnourished  6 8.9 (11.2) 0.263  6/7 0.125 
        
ONS v no ONS  10 11.5 (7.8) 0.006  10/11 0.012 
Other comparisonsd  4 11.2 (49.9) 1.000  3/5 1.000 
        
Interventional studies  12 8.9 (9.6) 0.050  11/14 0.057 
Observational ± interventional  2 7.4 (0.4) 0.180  2/2 0.500 
        
Single centre studies  5 8.5 (12.9) 0.080  4/6 0.688 
Multi-centre studies  9 7.6 (9.7) 0.110  9/10 0.021 
        
ONS use <3 months  9 9.2 (7.1)d 0.008d  9/9 0.004 
ONS use ≥3 months  5 4.7 (40.1) 0.893  4/7 1.000 
        
ONS community  7 7.3 (9.0) 0.237  7/9 0.180 















  % cost-saving (continuous data) Cost saving (binary data)  











        
Modelling studies  3      7.59  0.109  3/3 0.250 
Other studies  11 8.52 (9.5) 0.062  10/13 0.092 
a
 Based on data presented in Table 3 1 
b
 One sample Wilcoxon signed rank test of the difference between groups (against a test value of 0). All 2 
median values are positive indicating a cost saving in favour of the ONS group 3 
c
 Binomial test (against test proportion of 0.5 (favouring or not favouring ONS group) 4 
d















Table 5 1 
Contribution of ONS and the overall intervention to healthcare costs according to prospectively undertaken studies which included 2 





Comparison Duration of 
intervention 
(months) 
Period of cost 
assessment 
(months) 
Details of costs  % costs due to  % costs hospital 
 
      ONS Interventiona  ONS group  Control group 







ONS v no 
ONS 
~0.5 ~1.7 Costs include staff 
time, consumables, 
ward costs, ward-




 ~1 ~1  >90 >90 







ONS v no 
ONS 



















Comparison Duration of 
intervention 
(months) 
Period of cost 
assessment 
(months) 
Details of costs  % costs due to  % costs hospital 
 
      ONS Interventiona  ONS group  Control group 
community 
(post-op) 







ONS v no 
ONS 
~1.25 ~1.7 As aboveb  <3 <3  >90 >90 










D v routine 
care 
Hospital 











care) and indirect 
costs (absenteeism 



















Comparison Duration of 
intervention 
(months) 
Period of cost 
assessment 
(months) 
Details of costs  % costs due to  % costs hospital 
 
      ONS Interventiona  ONS group  Control group 
paid and unpaid 
labour) 




Community ONS v no 
ONS 
3.1 6 Cost of GP 
consultations, district 










 87 80 









>3e 12 Hospital admissions, 
visits by GP, 
physiotherapist, and 
other specialists, 



















Comparison Duration of 
intervention 
(months) 
Period of cost 
assessment 
(months) 
Details of costs  % costs due to  % costs hospital 
 
      ONS Interventiona  ONS group  Control group 
examinations and 
other costs.  
a
 In the case of Neelemaat et al 2012 the intervention included more than ONS (see column 3) 1 
bThe calculations of hospital cost were based on bed-day costs which included the cost of surgery (the original paper by Smedley et al18 excluded the cost of 2 
surgery). The non-hospital costs were based on Smedley et al18. 3 
cAssessed during the 3 months after discharge from hospital 4 
dBased on costs of supplements (£308.14) estimated from the BAPEN report 12). The range allows for ±15% uncertainty for the cost of the supplements (in 5 
reality a mixture of supplements) as well as an apparent discrepancy between two sets of calculated total costs reported in the original paper. 6 
eSince the cost for ONS was €565 per patient, an estimated duration of 3 months of ONS administration is likely to be a conservative estimate (€565 could have 7 
















Table 6  2 
Cost-effectiveness analyses in the community setting with quality adjusted life year  3 




Norman et al 201113 
 
 




Conditions (age of patients) Benign gastrointestinal conditions 
(mean age 51 years) 
 
Wide range of medical and 
surgical conditions (> 60 years; 
mean age 74.5 years) 
Intervention ONS + dietary counselling v 
dietary counselling 
ONS, dietary counselling and vit 
D + calcium v routine care 
Costs Direct healthcare costs of 
supplement only 
Direct healthcare costs + direct 
non-healthcare costs + indirect 
healthcare costsa 
Quality of life tool SF-36 EQ-5D 
Average incremental cost effectiveness ratio:   
    ‘Cost/QALY’b €12,099 (high price ONS) 
€9,497 (low price ONS) 
€26,962c 
    ‘Cost/unit’ improvement in functional 
          limitation (scale 0-6)     
 €618 
    ‘Cost/unit’ improvement in physical 
          activity (scale 0-6)     
 €4,470 
a
 Direct healthcare costs accounted for 94.4% of the total costs in the intervention group and 94.6% in the 5 
control group.  6 
b
 cost/QALY’ = extra cost per QALY gained (Incremental cost effectiveness ratio). A negative sign 7 
indicates that there is an overall cost saving. 8 
c
 The result shown is the main analysis involving intention to treat analysis for patients who did not die. 9 


















Figure 1. Flow diagram of publication included and excluded in the review (RCTs = 4 




1st pass exclusion: 
N = 16,547 
2nd pass exclusion:  
Reasons for exclusions 
(N=39) 
• 23 no ONS/no ONS costs 
• 7 review articles with no   
additional relevant studies 
identified 
• 4 disease-specific feeds 
(“immunonutrition”) 
• 1 ongoing or proposed 
study 
• 2 not standard ONS 
• 1 not intervention 




N = 6,221 
Database searches  
Potential studies 
N = 22,819 
Included:  
N = 16,598 
Included: N = 58 
Included:  
19 publications:  
• 9 full text papers (5 RCTs, 1 
observational study, 3 based on 
retrospective analysis of data, 
mainly from RCTs) 
• 9 abstracts  
• 1 report (with retrospective 
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 2 
Figure 2. Upper Forest plot of absolute cost savings expressed in national currency units 3 
(GBP = British pound; Euro = European currency unit) Lower Standardised meta-4 
analysis of costs in the ONS and comparison (control) groups based on RCTs. A negative 5 
value indicates a cost saving in favour of the ONS group. The setting of ONS 6 
administration is indicated (C = community; CHC = community followed by hospital and 7 
in the community again after discharge from hospital; HC = hospital followed by the 8 
community; C(pre-op) = preoperatively although it may have been continued for a short 9 

















Figure 3.  Meta-analysis of hospitalization in the ONS and comparison (control) groups 2 
based on RCTs. The results expressed as a percentage of control group (negative values 3 
indicate a cost saving in favour of the ONS group; C = community; CHC = community 4 
followed by hospital and in the community again after discharge from hospital; HC = 5 
hospital followed by the community; C(pre-op) = preoperatively although it may have 6 
been continued for a short period in hospital before surgery). a=proportion of patients 7 
admitted; b = N admission/patient; c = proportion of study period spent in hospital; d= 8 
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Supplementary file 1 (Details of included studies and further 1 
meta-analyses) 2 
A systematic review of the cost and cost effectiveness of using standard oral 3 
nutritional supplements in community and care home settings 4 
 M. Elia, C. Normand, K Norman, A Laviano  5 
      This supplementary file contains additional information on the included studies and on 6 
meta-analyses. 7 
1 Details of included studies 8 
1. 1 General features of included studies 9 
     Table 1 indicates the general study characteristics  1-23 (including abstracts8, 15-18, 20-23, 10 
which are identified below) and the funding source..These studies were either single centre or 11 
multi-centre studies involving either malnourished (e.g. 3-5, 7, 9, 10, 12-14) or a combination of 12 
malnourished and non-malnourished subjects (e.g. 1, 14, 19-22). The BAPEN report included 13 
both single-3, 4, 6 and multi-centre studies1, 7 in which ONS is given in the community setting 14 
(±  hospital).  The intervention was generally targeted at specific patients, who were typically 15 
randomised to receive ONS or no ONS (patient level intervention), but in two care home 16 
studies (both reported as abstracts), it was targeted at the institution which were studied 17 
before and after implementation of policies that applied to all residents with a wide range of 18 
clinical conditions (institution level intervention) 20, 21.  19 
1.1.1 Cost analysis  20 
     Nine publications involved administration of ONS in the community only (papers10-14; 21 
abstracts15-18), three in hospital and the community (papers,5, 9 and abstract8) and one a 22 
combination of the above (a component in the community alone and other components in 23 
community and hospital)1 (additional data in the BAPEN report from personal 24 















and community settings, the sequence of ONS administration varied (Table 1): in the 1 
community followed by hospital (surgical studies)1, 2, 5; in hospital and post discharge from 2 
hospital1, 2, 9; and before (community), during (hospital) and after (community) admission to 3 
hospital1, 8. Of the nine primary studies with prospective cost analyses (papers1, 9, 11, 14, 19, 4 
abstracts8, 20-22) one was an observational study with a parallel design14 and eight were 5 
interventional studies (six of which were RCTs (papers1, 9, 11, 19; abstracts8, 22) and two others 6 
with ‘before and after’ designs (abstracts20, 21). Most publications (papers5, 10, 12, 13, abstracts16-7 
18, 20, 23) reported retrospectively analysed data, including the BAPEN report 24, which 8 
undertook 10 cost analyses using data from six  published papers of RCTs1-4, 6, 7.  9 
     Only four studies with cost analyses involved care homes: an RCT22, two  studies with a 10 
before-and-after design (abstracts20, 21) and another based on modelling (abstract)23. 11 
    Only two studies, reported as abstracts, appear to have considered the cost of both 12 
screening and assessment. One of these was a  prospective care home study21 and the other of 13 
a modelling study in the community15(personal communication, A Cawood).  14 
1.1.2 Cost-effectiveness analysis 15 
     Of the four prospective RCTs with cost-effectiveness analyses (papers 9, 10, 19, abstract22) 16 
one started with ONS in hospital and continued in the  community(12), another in the 17 
community after recruitment from hospital10, and the other two in care homes 19, 22. 18 
Publications5, 12, 13  in which the costs were not quantitatively related to specific effectiveness 19 
outcome measures were included in the ‘cost-analysis’ category. 20 
1.2. Country  21 
1.2.1. Cost analysis 22 
     Prospective cost analyses were undertaken in the UK (papers1, 11 abstracts 21, 22), the 23 
Netherlands9,  France14, and the Czech Republic (abstract8).  The BAPEN report24 included 24 















reported retrospective analyses based on costs and tariffs from specific countries 1 
(Netherlands (papers 5, 12,abstracts16, 17),  Germany (papers10, 12 abstracts18, 23), UK 2 
(abstract15)), but modelling studies typically used clinical information gathered in other 3 
countries (full text papers5, 12, 13) or unspecified countries (all abstracts15-18, 23). Of 31 cost 4 
analyses, 16 were based on clinical data from the UK.  5 
1.2.2 Cost-effectiveness analysis 6 
     The four cost-effectiveness analyses were based on studies undertaken in the 7 
Netherlands9, Germany25, USA (care home study19), and the UK (care home study reported 8 
only as an abstract22).  9 
1. 3. Intervention v. alternative group 10 
     The following comparisons were made in community studies (± hospital): ONS v. no 11 
ONS (papers1, 5, 10, 12, 13 and abstracts16-18); ONS plus dietary advice plus calcium/vitamin D v. 12 
routine care9; ONS plus dietary advice v. routine care11; and the cost of treating malnourished 13 
patients in high v. low ONS prescribing general practices14.  Modelling studies depended on a 14 
range of previously published clinical data in which the comparison was ONS v. no ONS, 15 
with the exception of one which compared the group taking ONS with a range of alternative 16 
groups (standard care, placebo, dietary advice and/or normal diet; abstract15), to reflect the 17 
designs of clinical trials that underpinned the model. The BAPEN report included studies that 18 
made various types of comparisons: ONS v. no ONS1; ONS v. routine care 4; ONS v. placebo 19 
capsules6; and ONS plus dietary advice v. routine care (dietary advice when needed)7.   20 
     In the care home studies, the comparisons were as follows: ONS v. snacks taken between 21 
meals (plus a control group for further comparisons)19;‘Malnutrition Universal Screening 22 
Tool’ (‘MUST’) framework of nutritional care which includes ONS v. routine care 23 
(abstracts20, 21); ONS v. dietary advice (abstract22); and ONS v. no ONS (abstract23). 24 















     Cost analyses were based on short-term administration of ONS in the community (<3 1 
months, and as short as 15 days) as well as long-term administration (≥3 months, and up to 8 2 
months in some patient groups). The amount of ONS ingested ranged from 259-720 kcal/day 3 
depending on the study and setting. Some studies reported only the amount of ONS 4 
prescribed and several abstracts did not report either the amount or duration of prescription. 5 
Details are shown in Table1.  6 
1.5. Primary and secondary outcomes 7 
     The only clinical study in the community, in which the primary outcome measure was a 8 
cost analysis, was a long-term observational study comparing the cost of treating 9 
malnourished patients at general practices with a history of high v. low rates of ONS 10 
prescriptions14. Another report suggested that the primary aim was a cost-effectiveness 11 
analysis9, but this appears to be contradicted in other publications of the same RCT 9, 26, 27, 12 
including  a thesis describing the overall design of the RCT which indicated that the primary 13 
outcome was a change in activities of daily living (also stated in one of the publications that 14 
reported sample size calculations based on functional status26). Another paper, which stated 15 
that it aimed to assess the cost-effectiveness analysis of ONS, was based on clinical data of a 16 
previously published clinical trial, which primarily aimed to investigate the effect of ONS on 17 
functional status and body composition25.  In three community studies (papers 1, 11, abstract8)  18 
two of which had a hospital component1, 8, a secondary outcome measure was a cost analysis.   19 
     Within the care home setting, one study did not make it clear if the cost-effectiveness 20 
analysis was the primary or secondary outcome measure19. It stated that it aimed to address 21 
three outcomes (total caloric intake, staff time required to implement the interventions, and 22 
cost effectiveness) without specifying the primary outcome measure and without undertaking 23 















was  a cost-effectiveness analysis (abstract22). Two other prospectively undertaken care home 1 
studies, reported only in abstract form, also provided some economic data20, 21.  2 
     In abstracts of economic models in the community and care home settings, the primary 3 
outcome was a cost analysis established using national tariffs for specific countries and 4 
clinical data from various countries (papers5, 12, 13) or an unspecified source of clinical data 5 
(abstracts15-18, 23). 6 
 7 
1.6. Sample size calculations 8 
None of the publications included sample size calculations for costs or cost effectiveness.   9 
 10 
2. Meta-analyses 11 
Two sets of additional meta-analyses are presented below, one involving costs and the other 12 
hospitalisation. 13 
2,1. Costs 14 
    In the main paper Figure 2 shows two forest plots of prospective cost analyses based on 15 
randomised controlled trials undertaken in the community (± in hospital). The upper forest 16 
plot was not linked to a meta-analysis because the costs from these studies, which were 17 
undertaken in different countries at different times, are reported in various national currency 18 
units. The lower forest plot shows the results expressed as standardised differences, which 19 
were amalgamated using a random effects meta-analysis to produce summary statistics (-20 
0.059 (se 0.111); P = 0.594). A series of subgroup meta-analyses were also undertaken. The 21 
first of these, which involved three datasets from only one study1 involving  patients 22 
undergoing abdominal surgery who were given ONS in the community (± subsequently in 23 
hospital). The meta-analysis showed a net cost saving of borderline significance in favour of 24 
the ONS group, irrespective of whether the results were expressed in British pounds (£318.92 25 















0.253 (se 0.130), P = 0.053); I2 = 0%, P = 0.003).  The second of the meta-analyses involved 1 
the addition of another study in which ONS was given in both hospital and community 2 
(standardised difference, -0.127 (se 0.098), P = 0.193 (4 datasets); I2 = 0%, P = 0.546). The 3 
third meta-analysis involved the addition of yet another study in which ONS was given to 4 
patients recently discharged from hospital11 and resulted in the standardised difference 5 
becoming even smaller  (-0.067 (se 0.096), P = 0.491 (5 datasets);  I2 = 14%, P = 0.322). 6 
Although all meta- analyses favoured the ONS group, none was significant. 7 
2.2. Hospitalisation 8 
     The main paper reported that a series of meta-analysis involving 10 datasets from eight 9 
publications1, 6, 7, 9-11, 14, 28 had been undertaken.  The surgical study of Smedley et al1 provided 10 
three datasets that compared a control group receiving no ONS with three groups receiving 11 
ONS in the community (± hospital); the first receiving ONS pre-operatively only; the second 12 
before, during and after hospitalisation; and the third during and after discharge from hospital.              13 
     When only the longer term studies of three or more months of ONS supplementation6, 7, 9-14 
11, 14
 were included in the meta-analysis, hospitalisation was reduced as much as 20% in 15 
favour of the ONS group (point estimate 20.3% (se 6.4%), P=0.001; 6 datasets, N = 747 16 
subjects; I2 =26%, P = 0.239). When only the short-term (<3 months of ONS supplementation) 17 
surgical studies were included in the meta-analysis1, 8 hospitalisation was also reduced in 18 
favour of the ONS group (12.9%, (se 4.9%), P = 0.008; 4 datasets, N = 383); I2 = 0%, P = 19 
0.716).  And when only the surgical studies involving pre-operative ONS administration in 20 
community component are considered there was little change in the result (14.9%, (se 5.4%), 21 
P = 0.007; 5 datasets, N = 304); I2 = 0%, P = 0.694).  22 
     A meta-analysis involving both long-term and short-term studies showed an overall 23 
reduction in hospitalization in favour of the ONS group by 17.3% (se 3.6%; P < 0.001; 10 24 















Battandier et al14, the only one that was not a RCT, was excluded (14.9%, (se 4.4%), P = 1 
0.001; 9 datasets, N = 819 subjects); I2 =7%, P = 0.380). And finally when only the full text 2 
papers are considered in the meta-analysis (this involved removing the study of Manasek et 3 
al8, the only study reported in abstract form) the reduction in hospitalisation again favoured 4 
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UK = United Kingdom; US = United States; NL = Netherlands; CL = Chile; CR = Czech Republic; DE = Germany; FR = France; RCT = randomised controlled trial; Gp = 1 
group; ONS = oral nutritional supplement; BMI = body mass index; BAPEN= British Association for Enteral and Parenteral Nutrition; BW = body weight; ‘MUST’ = 2 
‘Malnutrition Universal Screening Tool’; CEA = cost-effectiveness analysis; ICER = incremental cost-effectiveness ratio; QALY = quality adjusted life year; GI = 3 
gastrointestinal; SGA = Subjective Global Assessment; MNA = Mini Nutritional Assessment; MMSE = Mini Mental State Examination; Abst = abstract 4 
a
 In cost-effectiveness studies, ‘cost /effectiveness measure’ represents the extra cost per unit effectiveness measure gained e.g. ‘cost/QALY’ = extra cost per quality adjusted 5 
life year gained.  6 
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Supplementary file 2 (Assessment of the risk of bias) 1 
A systematic review of the cost and cost effectiveness of using standard oral nutritional 2 
supplements in community and care home settings 3 
 M. Elia, C. Normand, K Norman, A Laviano  4 
      5 
This supplementary file contains additional information on the risk of bias associated with the 6 
papers included in the review. 7 
     Table 1 shows a summary of the assessment of the quality of RCTs (based on Cochrane 8 
Handbook for Systematic reviews of Interventions1) and Table 2 the quality of studies with 9 
economic data (based on the criteria provided by Drummond et al2). Since the RCT and economic 10 
criteria differ and since the same study may score very differently depending on the type of 11 
criteria used, specific economic and non-economic criteria were applied to individual as well as 12 
groups of studies to enable an overall judgement on the risk of bias to be made. A narrative 13 
discussion of the potential risk of bias is provided in the text below as well as in the main paper 14 
including the limitations of assumptions used in modelling studies, which may be based on a 15 
combination of economic outcomes and clinical outcomes derived from both RCTs and 16 
observational studies). 17 
   Overall, the potential risk of bias among most reviewed studies was considered to be medium. 18 
The method of randomisation was not stated in several studies, and blinding not stated to have 19 
been undertaken, although in one study the investigators were blinded to certain aspects of the 20 
trial3. There were two RCTs with no dropouts, another with 2% dropouts, and the remaining 10 21 
RCTs with 6-42% dropouts. One study indicated that it used intention to treat analysis using 22 
unstated methodology4 and another using multiple imputation3, although the calculations did not 23 
include those who died, despite the influence of death on cost-effectiveness (cost-utility) analyses 24 















characteristics5-7 that were not adjusted for using statistical analyses.  The single observational 1 
study8 (not included in Table 8 of RCTs) was considered potentially to be subject to at least 2 
moderate or high risk of bias, according to the STROBE criteria9. The reasons for 3 
dropouts/excluded subjects were not reported. A follow up rate of 74% of patients was reported in 4 
three districts and only 41% from another district (n= 59 patients), the latter being excluded from 5 
the analysis because the investigators felt that the data were of poor quality. The study also 6 
excluded outliers with unusually high costs, and also costs associated with medical care 7 
utilisation were not considered to be directly related to malnutrition (including falls), in an 8 
attempt to reduce variability. The two groups in this study also differed significantly in certain 9 
baseline characteristics, such as housing status, nutritional status, nutrition-related morbidities and 10 
prescription of drugs affecting gastrointestinal function, but attempts were made to adjust for 11 
baseline differences in the regression analysis using the propensity score method. 12 
     The only full text paper of a pilot study involving care home residents10 was also considered to 13 
be at potentially substantial risk of bias. In the presence of a 27% dropout rate, and a highly 14 
significant baseline imbalance between the control group and the two intervention groups in the 15 
between meal costs, an intention to treat analysis with statistical adjustments was not undertaken. 16 
The dietary intake methodology, the main outcome measure, may also be potentially at risk of 17 
some bias, since 56% of residents had a measured intake that was below their estimated resting 18 
energy needs (implying that the mean reported energy intake would fall well below their 19 
estimated total energy needs) but their weight tended to increase rather than decrease. 20 
     The studies reporting economic outcomes in the primary papers generally met most of the 21 


















Table 1 1 
Quality assessment of randomised controlled trials involving interventions with ONS and comparability of groups at baselinec (based on 2 
reference1) 3 
















        





Sealed envelopes  None stated N/A Yes (15%) 
 
No Yes with the 
exception of BMI 
which was lower in 
control group than 
the group that 
received ONS pre- 
and post-operatively 
        
Neelemaat et al 
20123  





the analyses was 
Unclear Limited (17% 
excluding deaths) 


































use of opaque 
envelopes 
not aware of 
patient group 
allocation 
imputation used only 
for those who 
survived)  
 









kept by co-worker 















        





No (Open label 
trial) 



































a) Hirsch et al 
19937 
Yes Not stated None stated N/A Yes (22%) No Yes, including liver 
function, but renal 
function was 
significantly worse in 
the control group 
b) Wilson et 
al 200113 
Yes Not stated None stated N/A (0%) N/A Yes (experimental v 
control group) 
        
c) MacFie et 
al 200014 
Yes, with double 
randomisation, one 
before surgery for pre-
operative ONS + diet or 
diet alone, and the other 
after surgery for post-
operative ONS + diet or 
Not stated None stated N/A Yes (7%, all 
before surgery) 
No (but N/A if only 
post-operative ONS 

































        





None stated N/A Yes (8% overall; 
7% after 
randomisation) 
No Yes, except the ONS 
group was younger 
than the control 
group by a mean of 8 
years 
        










































        
Simmons et al 
201010 
Yes Not stated None stated N/A No (27%; but 
unclear if this 
includes deaths) 
No Yes 
N/A = Not applicable 1 
aExcludes deaths except when otherwise indicated 2 
bIntention-to-treat defined according to CONSORT 2010 (A strategy for analyzing data in which all participants are included in the group to which they were 3 
assigned, whether or not they completed the intervention given to the group) [http://www.consort-statement.org/resources/glossary/e---l/intention-to-treat-4 
analysis/ Accessed March 2014]. 5 
cIn those studies in which baseline imbalance was found, no statistical adjustments were made 6 















Table 2 1 
Check-list for assessing economic evaluations (adapted from Drummond et al 2005)2 2 
Checklista,b,c,d,e,f Cost-effectiveness analysis   Cost analysis 
 Neelemaat 















et al 20048 
1 Was a well-defined question posed in 
answerable form? 
√  √ √ 2/3 (i,ii)  √ √ √  √ 
2.a Was a comprehensive description of 
the competing alternatives given? (that 
is, can you tell who did what to whom, 
where, and how often?) 
√ x √  √ √ √  √ 
3.b Was the effectiveness of the 
programmes or services established and 



















Checklista,b,c,d,e,f Cost-effectiveness analysis   Cost analysis 
 Neelemaat 















et al 20048 
4.c Were all the important and relevant 
costs and consequences for each 
alternative identified?h 
√ xi √  √ √ √  √ 
5. Were costs and consequences 
measured accurately in appropriate 
physical units (for example, hours of 
nursing time, number of physician 
visits, lost work-days, gained life-
years)? 
√ √ √  √ √ √  √ 




; iii N/A) 
√2/4 (i,iv)  √ √ √3/4 
(i,ii,iii; iv 
N/A) 
















Checklista,b,c,d,e,f Cost-effectiveness analysis   Cost analysis 
 Neelemaat 















et al 20048 
7.  Were costs and consequences 
adjusted for differential timing? 
N/A N/A N/A  N/A N/A N/A  N/A 
8.  Was an incremental analysis of costs 
and consequences of alternatives 
performed? 
√ √ √  N/A √ √  √ 
9.e Was allowance made for uncertainty 
in the estimates of costs and 
consequences? 
√ √ √ 2/3 (i;iii)  √ 1/3(i; ii 
N/A) 
√ 2/3 (i N/A) √ 2/3 
(ii,iii;i 
N/A) 
 √ 1/3 (iii) 
10.f Did the presentation and discussion 
of study results include all issues of 
concern to users? 
√  √ (ii) √ 4/5 
(i,ii,iv,v) 
 √ 3/5 (ii-iv;i 
N/A) 
√ 1/5 (i) √ 3/5 
(i,ii,iv) 
 √ 2/5 (ii,v) 
N/A = not applicable. 1 
a, b,c,d,e,f
















 Search strategy for systematic review considered not relevant 1 
h
 Q4 (iii) capital costs considered not relevant    2 
i
 Only cost considered was that of the ONS (authors state this was because the study was a pilot study). 3 
√ This character is used to indicate appropriate practice (rather than ‘yes’ or ‘no’ each of which can be the appropriate answer to specific questions). The 4 
Roman numerals indicate the question that was considered to be adequately fulfilled and the Arabic numbers refer to the proportion of questions that were 5 
adequately fulfilled on that topic (e.g. 1/3 (iii) indicates that only one (item iii) out of three questions was adequately fulfilled). 6 
 7 
 8 
1. (i) Did the study examine both costs and effects of the service(s) or programme(s)? (ii) Did the study involve a comparison of alternatives? (iii) Was a 9 
viewpoint for the analysis stated and was the study placed in any particular decision-making context? 10 
2. (i) Were any relevant alternatives omitted? [aThis question was omitted from the evaluation because it is almost always possible to omit a relevant 11 
alternative e.g. composition and texture of ONS] (ii) Was (Should) a do-nothing alternative (be) considered? 12 
3. (i) Was this done through a randomised, controlled clinical trial?  If so, did the trial protocol reflect what would happen in regular practice? (ii) Were 13 
effectiveness data collected and summarised through a systematic overview of clinical studies? [bThis question was omitted because formal systematic 14 
reviews are not generally included in primary reports of clinical studies] If so, were the search strategy and rules for inclusion or exclusion outlined? (iii) 15 















4.  (i) Was the range wide enough for the research question at hand? [cQuestion (i) was evaluated but the next two were not because they were considered 1 
ambiguous or irrelevant] (ii) Did it cover all relevant viewpoints? (Possible viewpoints include the community or social viewpoint, and those of patients 2 
and third-party payers.  Other viewpoints may also be relevant depending upon the particular analysis.) (iii) Were capital costs, as well as operating 3 
costs, included? 4 
5. (i) Were the sources of resource utilisation described and justified? (ii) Were any of the identified items omitted from measurement?  If so, does this 5 
mean that they carried no weight in the subsequent analysis? (iii) Were there any special circumstances (for example, joint use of resources) that made 6 
measurement difficult?  Were these circumstances handled appropriately? 7 
6. (i) Were the sources of all values clearly identified?  (Possible sources include market values, patient or client preferences and views, policy-makers’ 8 
views and health professionals’ judgements.) (ii) Were market values employed for changes involving resources gained or depleted? (iii) Where market 9 
values were absent (for example, volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were 10 
adjustments made to approximate market values? (iv) Was the valuation of consequences appropriate for the question posed (that is, has the appropriate 11 
type or types of analysis – cost-effectiveness, cost-utility, cost-benefit – been selected)? 12 
7. (i) Were costs and consequences that occur in the future ‘discounted’ to their present values? [dDiscounting was considered necessary only for studies 13 
with a duration of longer than one year] (ii) Was any justification given for the discount rate used? 14 















9. (i) If patient-level data on costs or consequences were available, were appropriate statistical analyses performed? (ii) If a sensitivity analysis was 1 
employed, was justification provided for the ranges of distributions of values (for key study parameters), and the form of sensitivity analysis used? [eA 2 
comparison of results obtained with intention to treat analysis and per protocol analysis was considered to be a type of sensitivity analysis, especially 3 
when the number of subjects in the ‘per protocol’ or ‘as completed’ analysis was substantially reduced] (iii) Were the conclusions of the study sensitive 4 
to the uncertainty in the results, as quantified by the statistical and/or sensitivity analysis? [This question is not addressed by this table, but it is 5 
considered in the text] 6 
10. (i) Were the conclusions of the analysis based on some overall index or ratio of costs to consequences (for example, cost-effectiveness ratio)?  If so, was 7 
the index interpreted intelligently or in a mechanistic fashion? (ii) Were the results compared with those of others who have investigated the same 8 
question?  If so, were allowances made for potential differences in study methodology? (iii) Did the study discuss the generalisation of the results to 9 
other settings and patient/client groups? [f Any discussion relevant to alternative care settings and/or patient/client groups was considered to satisfy this 10 
criterion] (iv) Did the study allude to, or take account of, other important factors in the choice or decision under consideration (for example, distribution 11 
of costs and consequences, or relevant ethical issues)? (v) Did the study discuss issues of implementation, such as the feasibility of adopting the 12 
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